![]() ![]() Heparin therapy may then be discontinued without tapering. ![]() To ensure continuous anticoagulation, it is advisable to continue full heparin therapy for several days after the prothrombin time has reached the therapeutic range. heparin infusion is used, prothrombin time can usually be measured at any time. In converting from heparin to an oral anticoagulant, the dose of the oral anticoagulant should be the usual initial amount and thereafter prothrombin time should be determined at the usual intervals. ![]() bolus and 24 hours after the last subcutaneous dose. This is about 5 hours after the last I.V. When an oral anticoagulant of the coumarin or similar type is to be begun in patients already receiving heparin sodium, baseline and subsequent tests of prothrombin activity must be determined at a time when heparin activity is too low to affect the prothrombin time. BLOCKASOL should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form. After deep subcutaneous (intrafat) injections, tests for adequacy of dosage are best performed on samples drawn 4 - 6 hours after the injections. Periodic platelet counts, haematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy, regardless of the route of administration. Dosage is considered adequate when the activated partial thromboplastin time (APTT) is 1.5 to 2 times normal or when the whole blood clotting time is elevated approximately 2.5 to 3 times the control value. When the drug is administered intermittently by intravenous injection, coagulation tests should be performed before each injection during the early stages of treatment and at appropriate intervals thereafter. When BLOCKASOL is given by continuous intravenous infusion, the coagulation time should be determined approximately every 4 hours in the early stages of treatment. The dosage of BLOCKASOL should be adjusted according to the patient’s coagulation test results. The intramuscular route of administration should be avoided because of the frequent occurrence of haematoma at the injection site. above the iliac crest or abdominal fat layer) injection. Heparin sodium is not effective by oral administration and should be given by intermittent intravenous injection, intravenous infusion, or deep subcutaneous (intrafat i.e. When heparin is added to an infusion solution for continuous intravenous administration, the container should be inverted at least 6 times to ensure adequate mixing and prevent pooling of the heparin in the solution. Prophylaxis and treatment of peripheral arterial embolism Īs an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures and in blood samples for laboratory purposes. Prevention of clotting in arterial and heart surgery Prophylaxis and treatment of pulmonary embolism ĭiagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation) (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease Elimination is by renal excretion mainly as metabolites with small amounts being excreted unchanged in urine.Īnticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension Heparin Sodium does not cross the placental barrier and is not distributed in human milk. Heparin Sodium does not have fibrinolytic activity therefore, it will not lyse the existing clots. Biotransformation takes place in the liver and the reticulo-endothelial system. Peak plasma levels of Heparin Sodium are achieved 2 to 4 hours following subcutaneous administration, although considerable individual variations are possible. use and within 20 - 30 minutes with subcutaneous use. Onset of anti coagulation is immediate with I.V. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Heparin acts at multiple sites in the normal coagulation system. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. BLOCKASOL is sterile solution of heparin sodium derived from porcine mucosa, standardized for anticoagulant activity. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |